Journal Mobile Options
Table of Contents
Vol. 83, No. 3, 1999
Issue release date: November 1999
Nephron 1999;83:246–249
(DOI:10.1159/000045517)

Apolipoprotein E Polymorphism in IgA Nephropathy

Yorioka N. · Nishida Y. · Oda H. · Watanabe T. · Yamakido M.
2nd Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aim: To clarify the role of the apolipoprotein E (Apo E) phenotype in IgA nephropathy, we investigated its relationship with histological damage and clinical factors. Methods: The subjects were 104 consecutive patients (41 men and 63 women) with IgA nephropathy. The Apo E phenotype was identified by plasma isoelectric focusing and immunoblotting, and the frequencies of Apo E alleles were calculated. Results: The frequencies of the phenotypes and the alleles were as follows: 2/2 = 0, 2/3 = 0.086, 3/3 = 0.654, 2/4 = 0.010, 4/3 = 0.211, 4/4 = 0.010, 3/5 = 0.029, ε2 = 0.048, ε3 = 0.817, ε4 = 0.120, and others = 0.015. There were no significant differences between the IgA nephropathy patients and healthy individuals in the frequencies of Apo E phenotypes and the alleles. However, the Apo E2 phenotype was significantly more common among patients with severe histological damage than in those with mild damage. The serum triglyceride levels were significantly elevated, and the Apo E2 phenotype was significantly more prevalent in patients with severe histological damage as compared with those with mild damage. Conclusion: The Apo E2 phenotype appears to be associated with the severity of histological damage in IgA nephropathy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Keane WF: Lipids and the kidney. Kidney Int 1994;46:910–920.
  2. Utermann G, Hees M, Steinmetz A: Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 1977;269:604–607.

    External Resources

  3. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1–21.
  4. Utermann G: Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433–440.
  5. Lehtimäki T, Moilanen T, Aalto-Setälä K, Kontula K, Porkka K, Åkerblom HK, Ehnholm C, Rönnemaa T, Viikari J: Association of apolipoprotein E and B polymorphisms with serum lipids. Ann Med 1991;23:657–662.
  6. Demant T, Bedford D, Packard CJ, Shepherd J: Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 1991;88:1490–1501.
  7. Mahley RW: Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988;240:622–630.
  8. Suzaki K, Kobori S, Ueno S, Uehara M, Kayashima T, Takeda H, Fukuda S, Takahashi K, Nakamura N, Uzawa H, Shichiri M: Effect of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990;80:181–189.
  9. Oikawa S, Suzuki N, Sakuma E, Saito T, Namai K, Kotake H, Fujii Y, Toyota T: Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 1991;18:553–558.
  10. Galla JH: IgA nephropathy. Kidney Int 1995;47:377–387.
  11. Kataoka S, Paidi M, Howard BV: Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. Clin Chem 1994;40:11–13.
  12. Kamboh MI, Ferrel RE, Kottke B: Genetic studies of human apolipoproteins. V. A novel rapid procedure to screen apolipoprotein E polymorphism. J Lipid Res 1988;29:1535–1543.

    External Resources

  13. Oda H, Yorioka N, Ueda C, Nishida Y, Yamakido M: Apolipoprotein E phenotype and renal disease; in Keane WF, Hörl WH, Kasiske BL (eds): Lipids and the Kidney. Contrib Nephrol. Basel, Karger, 1997, vol 120, pp 22–29.
  14. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, Utermann G: The apoliprotein E polymorphism: A comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991;49:338–349.
  15. Shigematsu H: Histological grading and staging of IgA nephropathy. Pathol Int 1997;47:194–202.
  16. Nishida Y, Yorioka N, Oda H, Yamakido M: Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis 1997;29:919–930.
  17. Nishida Y, Yorioka N, Oda H, Asakimori Y, Amimoto D, Yamakido M: Intermediate density lipoprotein is a DNA synthesis stimulation factor in cultured human mesangial cells. Nephron 1996;73:334–335.
  18. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, Alaupovic P: Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9:1482–1488.
  19. Taimela S, Lehtimäki T, Porkka KVK, Räsänen L, Viikari JSA: The effect of physical activity on serum total and low-density lipoprotein cholesterol concentrations varies with apolipoprotein E phenotype in male children and young adults: The Cardiovascular Risk in Young Finns Study. Metabolism 1996;45:797–803.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00